Anti-interleukin 5 therapies in severe asthma

Affiliations

¹ Allergy and Respiratory Diseases, Istituto di Ricovero e Cura a Carattere Scientifico San Martino-IST, University of Genoa, 16133 Genoa, Italy. Electronic address: passalacqua@unige.it.

Comment

Giovanni Passalacqua. Lancet Respir Med. 2017 Jul.

. 2017 Jul;5(7):537-538.

doi: 10.1016/S2213-2600(17)30206-0. Epub 2017 May 30.

¹ Allergy and Respiratory Diseases, Istituto di Ricovero e Cura a Carattere Scientifico San Martino-IST, University of Genoa, 16133 Genoa, Italy. Electronic address: passalacqua@unige.it.

No abstract available

Comment on

Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M; BISE Study Investigators. Ferguson GT, et al. Lancet Respir Med. 2017 Jul;5(7):568-576. doi: 10.1016/S2213-2600(17)30190-X. Epub 2017 May 22. Lancet Respir Med. 2017. PMID: 28545978 Clinical Trial.